145 related articles for article (PubMed ID: 31080561)
1. Exosome-based detection of activating and resistance
Castellanos-Rizaldos E; Zhang X; Tadigotla VR; Grimm DG; Karlovich C; Raez LE; Skog JK
Oncotarget; 2019 Apr; 10(30):2911-2920. PubMed ID: 31080561
[TBL] [Abstract][Full Text] [Related]
2. Exosome-Based Detection of
Castellanos-Rizaldos E; Grimm DG; Tadigotla V; Hurley J; Healy J; Neal PL; Sher M; Venkatesan R; Karlovich C; Raponi M; Krug A; Noerholm M; Tannous J; Tannous BA; Raez LE; Skog JK
Clin Cancer Res; 2018 Jun; 24(12):2944-2950. PubMed ID: 29535126
[No Abstract] [Full Text] [Related]
3. Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
Kim Y; Shin S; Lee KA
Cancer Cell Int; 2021 Jan; 21(1):50. PubMed ID: 33435996
[TBL] [Abstract][Full Text] [Related]
4. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
5. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
6. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
7. Selecting short length nucleic acids localized in exosomes improves plasma
Kim Y; Shin S; Kim B; Lee KA
Cancer Cell Int; 2019; 19():251. PubMed ID: 31582907
[TBL] [Abstract][Full Text] [Related]
8. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
9. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
10. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
11. Cross-Platform Comparison of Four Leading Technologies for Detecting
Xu T; Kang X; You X; Dai L; Tian D; Yan W; Yang Y; Xiong H; Liang Z; Zhao GQ; Lin S; Chen KN; Xu G
Theranostics; 2017; 7(6):1437-1446. PubMed ID: 28529628
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
[TBL] [Abstract][Full Text] [Related]
13. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
[TBL] [Abstract][Full Text] [Related]
14. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
Reckamp KL; Melnikova VO; Karlovich C; Sequist LV; Camidge DR; Wakelee H; Perol M; Oxnard GR; Kosco K; Croucher P; Samuelsz E; Vibat CR; Guerrero S; Geis J; Berz D; Mann E; Matheny S; Rolfe L; Raponi M; Erlander MG; Gadgeel S
J Thorac Oncol; 2016 Oct; 11(10):1690-700. PubMed ID: 27468937
[TBL] [Abstract][Full Text] [Related]
15. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
16. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].
Du J; Wang Z; Yang L; Di J; Zhang JG; Wang TY; Liu DG
Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):35-39. PubMed ID: 29365415
[No Abstract] [Full Text] [Related]
19. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients.
Xiong L; Cui S; Ding J; Sun Y; Zhang L; Zhao Y; Gu A; Chu T; Wang H; Zhong H; Ye X; Gu Y; Zhang X; Hu M; Jiang L
Oncotarget; 2017 Sep; 8(38):63846-63856. PubMed ID: 28969034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
